47 related articles for article (PubMed ID: 28657476)
1. Comparison of Peptide- and Lipid-Based Delivery of miR-34a-5p Mimic into PPC-1 Cells.
Urgard E; Brjalin A; Langel Ü; Pooga M; Rebane A; Annilo T
Nucleic Acid Ther; 2017 Oct; 27(5):295-302. PubMed ID: 28657476
[TBL] [Abstract][Full Text] [Related]
2. Developing Folate-Conjugated miR-34a Therapeutic for Prostate Cancer: Challenges and Promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
[TBL] [Abstract][Full Text] [Related]
3. An In Vitro Study for the Role of Schizophrenia-Related Potential miRNAs in the Regulation of COMT Gene.
Tonk O; Tokgun PE; Yılmaz ÖS; Tokgun O; Inci K; Çelikkaya B; Altintas N
Mol Neurobiol; 2024 Mar; ():. PubMed ID: 38427212
[TBL] [Abstract][Full Text] [Related]
4. Comparing two approaches of miR-34a target identification, biotinylated-miRNA pulldown vs miRNA overexpression.
Awan HM; Shah A; Rashid F; Wei S; Chen L; Shan G
RNA Biol; 2018 Jan; 15(1):55-61. PubMed ID: 29028450
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA-34a-5p: A pivotal therapeutic target in gallbladder cancer.
Oda T; Tsutsumi K; Obata T; Ueta E; Kikuchi T; Ako S; Fujii Y; Yamazaki T; Uchida D; Matsumoto K; Horiguchi S; Kato H; Okada H; Chijimatsu R; Otsuka M
Mol Ther Oncol; 2024 Mar; 32(1):200765. PubMed ID: 38596294
[TBL] [Abstract][Full Text] [Related]
6. Targeted delivery of miR-34a-5p by phenylborate-coupled polyethylenimide nanocarriers for anti-KSHV treatment.
Li F; Cao D; Yao L; Gu W; Liu Z; Li D; Cui L
Front Bioeng Biotechnol; 2023; 11():1343956. PubMed ID: 38260739
[TBL] [Abstract][Full Text] [Related]
7. Dual peptides-modified cationic liposomes for enhanced Lung cancer gene therapy by a gap junction regulating strategy.
Zhao Z; Wang W; Wang G; Huang Z; Zhou L; Lin L; Ou Y; Huang W; Zhang X; Wu C; Tao L; Wang Q
J Nanobiotechnology; 2023 Dec; 21(1):473. PubMed ID: 38066528
[TBL] [Abstract][Full Text] [Related]
8. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34.
Wiggins JF; Ruffino L; Kelnar K; Omotola M; Patrawala L; Brown D; Bader AG
Cancer Res; 2010 Jul; 70(14):5923-30. PubMed ID: 20570894
[TBL] [Abstract][Full Text] [Related]
9. Baicalin-modified polyethylenimine for miR-34a efficient and safe delivery.
Wang Y; Wang B; Xiao Y; Cai Q; Xing J; Tang H; Li R; Zhang H
Front Bioeng Biotechnol; 2023; 11():1290413. PubMed ID: 38026879
[TBL] [Abstract][Full Text] [Related]
10. Novel RNA molecular bioengineering technology efficiently produces functional miRNA agents.
Traber GM; Yi C; Batra N; Tu M; Yu A
RNA; 2024 Mar; ():. PubMed ID: 38429100
[TBL] [Abstract][Full Text] [Related]
11. Developing folate-conjugated miR-34a therapeutic for prostate cancer treatment: Challenges and promises.
Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
bioRxiv; 2024 Jan; ():. PubMed ID: 38045265
[TBL] [Abstract][Full Text] [Related]
12. In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation.
Cortez MA; Valdecanas D; Niknam S; Peltier HJ; Diao L; Giri U; Komaki R; Calin GA; Gomez DR; Chang JY; Heymach JV; Bader AG; Welsh JW
Mol Ther Nucleic Acids; 2015 Dec; 4(12):e270. PubMed ID: 26670277
[TBL] [Abstract][Full Text] [Related]
13. Role of autophagy in cell-penetrating peptide transfection model.
Dowaidar M; Gestin M; Cerrato CP; Jafferali MH; Margus H; Kivistik PA; Ezzat K; Hallberg E; Pooga M; Hällbrink M; Langel Ü
Sci Rep; 2017 Oct; 7(1):12635. PubMed ID: 28974718
[TBL] [Abstract][Full Text] [Related]
14. Chemical modification patterns for microRNA therapeutic mimics: a structure-activity relationship (SAR) case-study on miR-200c.
Garreau M; Weidner J; Hamilton R; Kolosionek E; Toki N; Stavenhagen K; Paris C; Bonetti A; Czechtizky W; Gnerlich F; Rydzik A
Nucleic Acids Res; 2024 Apr; 52(6):2792-2807. PubMed ID: 38421619
[TBL] [Abstract][Full Text] [Related]
15. A High-Throughput Small Molecule Screen Identifies Ouabain as Synergistic with miR-34a in Killing Lung Cancer Cells.
Rupaimoole R; Yoon B; Zhang WC; Adams BD; Slack FJ
iScience; 2020 Feb; 23(2):100878. PubMed ID: 32062455
[TBL] [Abstract][Full Text] [Related]
16. In Situ Monitoring of MicroRNA Replacement Efficacy and Accurate Imaging-Guided Cancer Therapy through Light-Up Inter-Polyelectrolyte Nanocomplexes.
Deng X; Yin Z; Lu J; Li X; Shao L; Zhao C; Yang Y; Hu Q; Wu Y; Sheng W
Adv Sci (Weinh); 2018 Apr; 5(4):1700542. PubMed ID: 29721409
[TBL] [Abstract][Full Text] [Related]
17. pH-Dependent Membrane Interactions of the Histidine-Rich Cell-Penetrating Peptide LAH4-L1.
Wolf J; Aisenbrey C; Harmouche N; Raya J; Bertani P; Voievoda N; Süss R; Bechinger B
Biophys J; 2017 Sep; 113(6):1290-1300. PubMed ID: 28734478
[TBL] [Abstract][Full Text] [Related]
18. N-peptide of vMIP-Ⅱ reverses paclitaxel-resistance by regulating miRNA-335 in breast cancer.
Wang Y; Wang H; Ding Y; Li Y; Chen S; Zhang L; Wu H; Zhou J; Duan K; Wang W; Chen C; Yang Q
Int J Oncol; 2017 Sep; 51(3):918-930. PubMed ID: 28731125
[TBL] [Abstract][Full Text] [Related]
19. Mesenchymal stem cell transplantation carried in SVVYGLR modified self-assembling peptide promoted cardiac repair and angiogenesis after myocardial infarction.
Gao XR; Xu HJ; Wang LF; Liu CB; Yu F
Biochem Biophys Res Commun; 2017 Sep; 491(1):112-118. PubMed ID: 28709866
[TBL] [Abstract][Full Text] [Related]
20. C-Peptide replacement therapy in type 1 diabetes: are we in the trough of disillusionment?
Pinger CW; Entwistle KE; Bell TM; Liu Y; Spence DM
Mol Biosyst; 2017 Jul; 13(8):1432-1437. PubMed ID: 28685788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
